

AMENDMENTS TO THE CLAIMS

Claims 1-20: (Canceled.)

21. (Currently Amended) A method of suppressing a rejection ~~of an organ transplant~~
~~rejection to a minor antigen in an allograft~~, comprising administering to ~~an organ transplant~~
recipient of said allograft an effective amount of a composition comprising a substance
having a function of decreasing a reduced glutathione content in at least one cell selected
from the group consisting of macrophages, monocytes and dendric cells, and thereby the
rejection to a minor antigen in said allograft is suppressed,

wherein the substance is at least one member selected from the group consisting of a
N, N'-diacylcystine, N, N'-diacylcystine ester, L-S, R-buthionine sulfoximine, R-buthionine
sulfoximine derivative and a maleic acid diester.

22. (Previously Presented) The method according to claim 21, wherein the substance
can reduce the glutathione content by at least 30% when incubated in vitro with macrophages
for from 1 to 24 hours.

23. (Currently Amended) The method according to claim 21, wherein the substance
~~the substance~~ has the function of decreasing a reduced glutathione content in macrophages.

24. (Withdrawn; Currently Amended) The method according to claim 21, wherein
the substance ~~the substance~~ has the function of decreasing a reduced glutathione content in
monocytes.

25. (Withdrawn; Currently Amended) The method according to claim 21, wherein the substance ~~the substance~~ has the function of decreasing a reduced glutathione content in dendritic cells.

26. (Currently Amended) The method according to claim 21, wherein the substance is ~~at least one member selected from the group consisting of a N, N'-diacylcystine, a N, N'-diacylcystine ester, busulfan, L-S, R-buthionine sulfoximine, R-buthionine sulfoximine derivative and a maleic acid diester.~~

27. (Currently Amended) The method according to claim 21, wherein the substance is a N, N'-diacylcystine.

28. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ allograft is at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

29. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ allograft is a part of at least one member selected from the group consisting of liver, lung, kidney, liver, heart, skin, cornea, and corneal epithelium.

30. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ allograft is at least one member selected from the group consisting of a cornea and corneal epithelium.

31. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ allograft is corneal epithelium.

32. (Canceled)

33. (Previously Presented) The method according to claim 21, wherein the composition is in the form of an oral drug, eye drop or infusion.

34. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ transplant recipient of said allograft is a mammal.

35. (Currently Amended) The method according to claim 21, wherein the ~~organ~~ transplant recipient of said allograft is a human.

36. (Previously Presented) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of an oral drug, eye drop and infusion.

37. (Previously Presented) The method according to claim 21, wherein the substance is administered in at least one form selected from the group consisting of a pharmaceutical, food, drink and nutriment.

38. (Previously Presented) The method according to claim 21, wherein the composition is administered at a dose ranging from at least once a day to at least once every 5 days.

39. (Previously Presented) The method according to claim 21, wherein the composition is administered at a dose ranging from 1 mg to 10 g.

40. (New) The method according to claim 21, wherein the substance is a L-S, R-buthionine sulfoximine.

41. (New) The method according to claim 21, wherein the substance is a R-buthionine sulfoximine derivative.

42. (New) The method according to claim 21, wherein the substance is a maleic acid diester.